The Biden administration recently warned that Medicare could spend $3.5 billion on a new category of Alzheimer's drugs in 2025 alone – a figure vastly higher than what experts in the field predict – leading many to question the math.
Marvell Adams Jr.
Advertisement
Articles by Marvell Adams Jr.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
How AI, online reviews and rising standards are redrawing the path to care
2
Nearly half of internal medicine's workforce was born abroad, new JAMA study finds
3
Why physicians can't collect Medicare Advantage copays like they used to
4
Patients now shop for doctors like consumers, and the bar just got higher
5